Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER).

Autor: Lambert J; a Department of Dermatology , Antwerp University Hospital, University of Antwerp , Edegem , Belgium., Ghislain PD; b Department of Dermatology, Cliniques Saint-Luc , Université Catholique de Louvain , Brussels , Belgium., Lambert J; c Department of Dermatology , Ghent University Hospital , Gent , Belgium., Cauwe B; d AbbVie SA/NV , Wavre , Belgium., Van den Enden M; d AbbVie SA/NV , Wavre , Belgium.
Jazyk: angličtina
Zdroj: The Journal of dermatological treatment [J Dermatolog Treat] 2017 Aug; Vol. 28 (5), pp. 394-400. Date of Electronic Publication: 2016 Nov 15.
DOI: 10.1080/09546634.2016.1255304
Abstrakt: Purpose: The present study aimed to evaluate current treatment patterns and achievement of treatment goals in Belgian patients with moderate-to-severe plaque psoriasis.
Materials and Methods: This cross-sectional observational study (DISCOVER) was conducted in 2011 - 2012 in Belgian dermatology centers. Patient data were collected during a single visit and included information on psoriasis management and severity (PASI and DLQI). Treatment success was defined according to the current European consensus treatment goal algorithm.
Results: Of the 556 patients included in the study, 38.1% reported no current treatment or only topicals, 34.2% were being treated with traditional systemics and/or phototherapy, and 29.5% with biologics. Methotrexate (11.7%) was the most commonly prescribed traditional systemic and adalimumab (14.2%) was the most commonly prescribed biologic agent at the time of the study. The percentage of patients achieving treatment goals was significantly higher in biologic-treated patients (73.1%) compared to those using traditional systemics (50.6%), phototherapy (41.1%), or no treatment/only topicals (20.9%; p < .001).
Conclusions: Nearly 40% of Belgian patients with moderate-to-severe psoriasis in the DISCOVER study were undertreated despite the severity of their disease. Undertreatment of psoriasis remains a problem in Belgium and more effective educational strategies are needed to ensure the best treatment outcome for these patients. [Formula: see text].
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje